MedTrace Logo

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

NCT02195232 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2021-03-03

Study results available
· View outcomes & findings →

Summary

This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.

Conditions

  • Thromboembolism of Vein VTE in Colorectal Cancer
  • Thromboembolism of Vein in Pancreatic Cancer
  • Thromboembolism of Vein in Non-small Cell Lung Cancer

Interventions

DRUG

Isoquercetin

Sponsors & Collaborators

  • Quercegen Pharmaceuticals

    collaborator INDUSTRY

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Jeffrey Zwicker, MD

    lead OTHER

Principal Investigators

  • Jeffrey Zwicker, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-12-31
Completion
2019-10-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02195232 on ClinicalTrials.gov